1. Medtech Insight
  2. >>Business

Galaxy Gets $18M To Advance Centauri Pulsed Field Ablation System

 
• By Reed Miller

ATP, a venture capital firm focused on life sciences, is providing the series A round to help Galaxy complete European and Canadian trials of its Centauri pulsed field ablation technology to treat atrial fibrillation.

electrophysiology map of atrial fibrillation
EP map, created by Abbott's Ensite, of a four-vein isolation ablation in Galaxy Medical's European study of the Centauri PFA system. • Source: Galaxy Medical

Galaxy Medical has secured an $18m series A financing to advance its Centauri pulsed field ablation (PFA) technology for treatment of atrial fibrillation.

The investment comes from ATP, a New York-based venture capital firm with $2.65bn committed to life sciences companies.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Edwards Lifesciences Holds 2025 EPS Outlook Despite Tariff Headwind

 
• By Shubham Singh

The brunt of the tariff exposure stems from Singapore and Costa Rica, which together account for an estimated 70% to 80% of the tariff-related cost burden. Less than 10% of the exposure is tied to China.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.